Fujifilm Diosynth Biotechnologies, a world-leading contract development and manufacturing organisation (CDMO) for biologics, vaccines, advanced therapies, and oncolytic viruses, has announced that the first phase of its expansion at the Hillerød site (Denmark) is ready to bring the new production capacity into operation.

This milestone marks the initial step in the company’s strategy to build a comprehensive global ecosystem dedicated to enhancing the production and delivery of life-saving medicines.

This first phase adds six mammalian cell bioreactors, bringing the total capacity at the Hillerød site to 12 x 20,000 L bioreactors. A previously announced major capital investment will support the next phase, which will include an additional 8 x 20,000 L bioreactors and two downstream processing streams.

By mid-2025, fill/finish production is scheduled to commence, with full expansion expected to be in operation by 2026, increasing the site footprint to approximately 51,500m² and creating up to 2,200 jobs.  

Since 2011, Fujifilm Corporation has invested over $8 billion to establish a formidable global network for biologics manufacturing. This includes strategically located modular facilities designed to provide the agility needed for rapid production scaling. In 2025, operations will begin at the first phase of Fujifilm Diosynth Biotechnologies’ large-scale facility in Holly Springs, North Carolina, further reinforcing the company’s commitment to building its transformative ecosystem. 

This expansion also aligns with the company’s sustainability initiative, Partners for the Planet, which incorporates sustainable practices across all facilities. The Hillerød site has signed a ten-year Power Purchase Agreement to source all electricity from renewable sources, contributing to its silver certification from the globally recognised EcoVadis standard.